Clinical antibiotic therapy disrupts microbial bile acid metabolism and depletes secondary bile acids without altering pulmonary antibacterial defense
Although clinical antibiotic therapy disrupts microbial bile acid metabolism and depletes secondary bile acids, this specific metabolic perturbation does not appear to mediate the impaired pulmonary antibacterial defense observed in patients.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Hospitals are places of healing, yet they are also environments where new infections can take hold. Among the most dangerous of these are pneumonia cases that develop after a patient has already been admitted, known as hospital-acquired pneumonia. These infections are a leading cause of death among healthcare-related illnesses, and a well-known risk factor for developing them is the prior use of antibiotics. While antibiotics are essential for killing harmful bacteria, they are broad-spectrum tools that often wipe out the vast community of beneficial microbes living in our intestines. Scientists have long suspected that this disruption of the gut's microbial ecosystem leaves the body vulnerable to new infections, but the exact mechanism has remained a mystery. One leading theory focused on a specific set of chemicals produced by these gut bacteria: secondary bile acids. These are molecules created when gut microbes transform primary bile acids, which the liver makes to help digest fats. These secondary bile acids are known to travel through the body and act as signals that can tune the immune system, potentially helping the lungs fight off invaders. The question researchers faced was whether the loss of these specific chemicals, caused by antibiotic treatment, was the direct reason patients became so susceptible to pneumonia.
A team of scientists at Charité – University Medical Center in Berlin set out to investigate this connection, moving from human patients to controlled experiments in mice to trace the path of cause and effect. They began by looking at the gut microbiomes of hospitalized patients who had received broad-spectrum antibiotics. Using advanced genetic sequencing, they examined the DNA of the bacteria in stool samples to see which microbial functions had been lost. They found that the antibiotics had indeed disrupted the specific genetic machinery bacteria use to convert primary bile acids into secondary ones. In the patients who had taken antibiotics, the genes responsible for this conversion were depleted, and the bacteria capable of performing this task were missing. When the researchers measured the actual chemicals in the patients' stool and blood, the pattern was clear: the levels of secondary bile acids had dropped significantly, while primary bile acids remained unchanged or even increased. This confirmed that the antibiotic treatment had successfully stripped the gut of its ability to produce these specific signaling molecules, and that this loss was not just local to the gut but was reflected in the bloodstream as well.
With this metabolic disruption confirmed in humans, the researchers needed to determine if it was the cause of the increased risk of lung infection. They turned to mice, first depleting their gut microbiota with a cocktail of antibiotics to mimic the human condition. As expected, these mice became much more susceptible to a severe strain of bacteria that causes pneumonia, allowing the infection to grow rapidly in their lungs. The critical test came next: the scientists tried to fix the problem by giving the antibiotic-treated mice extra secondary bile acids in their drinking water, effectively restoring the missing chemical signal. If the lack of these molecules was the true culprit, this should have protected the mice. However, the extra bile acids made no difference; the mice remained just as vulnerable to the lung infection as those who did not receive the supplement. To be absolutely certain, the team also tested mice that were genetically engineered to lack the receptor that secondary bile acids normally bind to, as well as mice treated with a drug designed to activate that same receptor. In every scenario, whether the receptor was missing, over-activated, or the chemical signal was restored, the mice's ability to fight off the lung bacteria remained unchanged.
The study also examined the immune cells in the lungs to see if the lack of bile acid signaling was causing a failure in the body's defense forces. They counted the various types of white blood cells and measured the levels of immune signaling proteins in the blood and lung fluid. The results showed no significant differences between the groups; the immune system's cellular composition and its chemical response to the infection were not altered by the absence of secondary bile acids or the status of their receptor. This evidence strongly suggests that while antibiotics do indeed disrupt the gut's production of secondary bile acids and deplete them from the body, this specific metabolic change is not the primary driver behind the increased risk of pneumonia. The researchers conclude that the heightened susceptibility to infection following antibiotic treatment is likely due to other factors, such as the general loss of colonization resistance that prevents bad bacteria from taking hold in the gut in the first place, rather than the loss of these specific immune-modulating chemicals. The work clarifies that while the gut and lungs are deeply connected, the pathway involving secondary bile acids is not the broken link that makes patients vulnerable to pneumonia after antibiotic therapy.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.